Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | POLA1 | P09884 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8812278 | 1.00 | TSHR (0.58) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL7293281 | 1.00 | TSHR (0.58) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL8811910 | 1.00 | TSHR (0.58) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL7284593 | 1.00 | TSHR (0.58) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL8814157 | 1.00 | TSHR (0.58) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL893479 | 1.00 | TSHR (0.58) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL8811115 | 1.00 | TSHR (0.58) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL7282104 | 1.00 | TSHR (0.58) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL893048 | 0.98 | TSHR (0.61) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL893425 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137499-A1 | BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-2048150-A1 | BENZYL PHENYL GLUCOPYRANOSIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5856334-A | ANTAGONIST FOR EOSINOPHILS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1999-01-05 | — | — | US | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0773219-A1 | IMIDAZOQUINOLINE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-14 | — | — | EP | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| US-5401722-A | Peptide analogues | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-03-28 | — | — | US | disclosed |
| EP-0481311-A2 | Aminoacid derivatives | MERCK PATENT GmbH (DE) | 1992-04-22 | — | — | EP | disclosed |
| EP-0474008-A1 | Amino acid derivatives | MERCK PATENT GmbH (DE) | 1992-03-11 | — | — | EP | disclosed |
| EP-0464517-A2 | Amino acid derivatives with renin inhibiting activity | MERCK PATENT GmbH (DE) | 1992-01-08 | — | — | EP | disclosed |
| EP-0456039-A2 | Renin inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1991-11-13 | — | — | EP | disclosed |
| EP-0446751-A1 | Glycolic acid derivatives | MERCK PATENT GmbH (DE) | 1991-09-18 | — | — | EP | disclosed |
| EP-0446485-A2 | Peptide analogues with renininhibiting activity | MERCK PATENT GmbH (DE) | 1991-09-18 | — | — | EP | disclosed |
| EP-0418696-A2 | Derivatives of aminoacids | MERCK PATENT GmbH (DE) | 1991-03-27 | — | — | EP | disclosed |
| CN-1037155-A | Amino acid derivative | MERCK PATENT GMBH (DE) | 1989-11-15 | — | — | CN | disclosed |
| EP-0339483-A2 | Renin inhbiting amino-acid derivatives | MERCK PATENT GmbH (DE) | 1989-11-02 | — | — | EP | disclosed |
| EP-0337334-A2 | Renin-inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | TSHR 2585/4885LMNA 1225/4885ALDH1A1 889/4885 |
| US-20090137499-A1 | BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE | SLC5A1, SLC5A2, SLC2A1 | TSHR 2115/4885LMNA 3975/4885ALDH1A1 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.